A phase 2 study of O-benzylguanine (O-BG) and temozolomide in patients with glioblastoma progressing at least 3 months after completion of primary treatment with radiation therapy and temozolomide.

Trial Profile

A phase 2 study of O-benzylguanine (O-BG) and temozolomide in patients with glioblastoma progressing at least 3 months after completion of primary treatment with radiation therapy and temozolomide.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Benzylguanine (Primary) ; Temozolomide (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Feb 2017 Status changed from completed to discontinued.
    • 22 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 27 Oct 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top